PRLS

(redirected from Primary Restless Legs Syndrome)
AcronymDefinition
PRLSPuerto Rican and Latino Studies (program of study)
PRLSPrepaid Rental Listing Service (California)
PRLSPotential Rotary Leadership Seminar (Rotary Club)
PRLSProjekta Reforme Lokalne Samouprave (Croatian: Local Government Reform Project)
PRLSPosterior Reversible Leukoencephalopathy Syndrome (medical disorder)
PRLSPrimary Restless Legs Syndrome
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Food and Drug Administration approved Horizant (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
The capacity of Horizant in the treatment of patients with moderate-to-severe primary Restless Legs Syndrome was demonstrated in two 12-week clinical trials in adults.
Pramipexole is approved by the Food and Drug Administration for the treatment of the signs and symptoms of idiopathic Parkinson's disease and for primary restless legs syndrome.
"We have several open-label studies showing that dopaminergic agents, pramipexole [Mirapex] in particular, are able to reduce [or] improve depressive symptoms in Parkinson's disease." Pramipexole is approved by the Food and Drug Administration for the treatment of the signs and symptoms of idiopathic Parkinson's disease and moderate to severe primary restless legs syndrome.
The efficacy of Horizant in the treatment of patients with moderate-to-severe primary Restless Legs Syndrome was demonstrated in two 12-week clinical trials in adults.
UCB on Tuesday announced that the US Food and Drug Administration (FDA) has approved Neupro for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease and as a treatment for moderate-to-severe primary Restless Legs Syndrome.
Pharmaceutical company GlaxoSmithKline (NYSE:GSK) and biopharmaceutical company XenoPort Inc (Nasdaq:XNPT) announced jointly on Wednesday the receipt of US Food and Drug Administration (FDA) approval for Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
19 January 2012 - Japan's Astellas Pharma Inc (TYO:4503) and US XenoPort Inc (NASDAQ:XNPT) said on Tuesday that Regnite (gabapentin enacarbil) has obtained approval in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
Horizant is under review for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Full browser ?